Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2024 Dec 23

PMID 39715984

Authors

Tieci Yi

Difei Lu

Yonggang Cui

Zheng Zhang

Xing Yang

Jianhua Zhang

Lin Qiu

Haoyu Weng

Lin Liu

Xiaojiang Duan

Guangyu Zhao

Wei Ma

Ying Gao

Yan Fan

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the diagnostic efficacy of Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients.

Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0.

Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of Ga-pentixafor SUV was 0.750 (95%CI 0.578-0.922, p = 0.026). The optimum SUV cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUV/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500-0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884).

Conclusions: Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUV or SUV/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered).

References

Nwariaku F, Miller B, Auchus R, Holt S, Watumull L, Dolmatch B . Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006; 141(5):497-502. DOI: 10.1001/archsurg.141.5.497. View

Jiang Y, Zhang C, Wang W, Su T, Zhou W, Jiang L . Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2015; 100(5):1837-44. DOI: 10.1210/jc.2014-3551. View

Quencer K . Adrenal vein sampling: technique and protocol, a systematic review. CVIR Endovasc. 2021; 4(1):38. PMC: 8093361. DOI: 10.1186/s42155-021-00220-y. View

Mulatero P, di Cella S, Monticone S, Schiavone D, Manzo M, Mengozzi G . 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab. 2012; 97(3):881-9. DOI: 10.1210/jc.2011-2384. View

Minami I, Yoshimoto T, Hirono Y, Izumiyama H, Doi M, Hirata Y . Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism. Endocr J. 2008; 55(5):839-46. DOI: 10.1507/endocrj.k07e-164. View

Zheng Y, Long T, Peng N, Zhen M, Ye Q, Zhang Z . The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism. J Clin Endocrinol Metab. 2023; 109(1):171-182. DOI: 10.1210/clinem/dgad421. View

Kobayashi H, Abe M, Soma M, Takeda Y, Kurihara I, Itoh H . Development and validation of subtype prediction scores for the workup of primary aldosteronism. J Hypertens. 2018; 36(11):2269-2276. DOI: 10.1097/HJH.0000000000001855. View

Turcu A, Yang J, Vaidya A . Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022; 18(11):665-682. DOI: 10.1038/s41574-022-00730-2. View

Loh K, Koay E, Khaw M, Emmanuel S, Young Jr W . Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000; 85(8):2854-9. DOI: 10.1210/jcem.85.8.6752. View

10.

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

11.

Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y . Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020; 47(11):2656-2665. DOI: 10.1007/s00259-020-04722-0. View

12.

Ng E, Gwini S, Zheng W, Fuller P, Yang J . Predicting Bilateral Subtypes of Primary Aldosteronism Without Adrenal Vein Sampling: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023; 109(2):e837-e855. DOI: 10.1210/clinem/dgad451. View

13.

Pasternak J, Epelboym I, Seiser N, Wingo M, Herman M, Cowan V . Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein. Surgery. 2015; 159(1):267-73. DOI: 10.1016/j.surg.2015.06.048. View

14.

Young W, Stanson A, Thompson G, Grant C, Farley D, van Heerden J . Role for adrenal venous sampling in primary aldosteronism. Surgery. 2005; 136(6):1227-35. DOI: 10.1016/j.surg.2004.06.051. View

15.

Rossi G, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C . A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006; 48(11):2293-300. DOI: 10.1016/j.jacc.2006.07.059. View

16.

Gao Y, Ding J, Cui Y, Li T, Sun H, Zhao D . Functional nodules in primary aldosteronism: identification of CXCR4 expression with Ga-pentixafor PET/CT. Eur Radiol. 2022; 33(2):996-1003. DOI: 10.1007/s00330-022-09058-x. View

17.

Heinze B, Fuss C, Mulatero P, Beuschlein F, Reincke M, Mustafa M . Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension. 2017; 71(2):317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975. View

18.

Funder J, Carey R, Mantero F, Murad M, Reincke M, Shibata H . The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(5):1889-916. DOI: 10.1210/jc.2015-4061. View

19.

Yin X, Ai K, Luo J, Liu W, Ma X, Zhou L . A comparison of the performance of Ga-Pentixafor PET/CT adrenal vein sampling for subtype diagnosis in primary aldosteronism. Front Endocrinol (Lausanne). 2024; 15:1291775. PMC: 10899670. DOI: 10.3389/fendo.2024.1291775. View

20.

Kempers M, Lenders J, van Outheusden L, van der Wilt G, Schultze Kool L, Hermus A . Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009; 151(5):329-37. DOI: 10.7326/0003-4819-151-5-200909010-00007. View